Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Axis Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$1,194,490

136 payments

Through program year 2025, Axis Clinical Trials is reported as receiving $1,194,490 in research payments, across 136 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $28,576 1
2023 Research $82,713 13
2022 Research $41,492 12
2021 Research $204,658 35
2020 Research $375,192 38
2019 Research $461,858 37

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vanda Pharmaceuticals Inc. $481,817 55 payments
  2. Eli Lilly and Company $310,991 7 payments
  3. Horizon Therapeutics plc $291,167 4 payments
  4. Sanofi US Services Inc. $38,070 53 payments
  5. Taro Pharmaceuticals USA, Inc. $30,000 2 payments
  6. Bausch Health US, LLC $24,600 9 payments
  7. Mylan Inc. $16,920 4 payments
  8. Amgen Inc. $822 1 payment
  9. Boehringer Ingelheim International GmbH $103 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis $481,817 55 payments
  2. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $245,356 3 payments
  3. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $169,902 2 payments
  4. A Randomized Double-Blind Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Randomized Controlled Trial RCT ) $67,892 1 payment
  5. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa Pegloticase Mirror Randomized Controlled Trial RCT $53,373 1 payment
  6. A Phase 1, Double-Blind, Two-Arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity Or Overweight, Without Diabetes $28,576 1 payment
  7. A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) $24,600 9 payments
  8. A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using Investigational 1-Ml and 2-Ml Prefilled Syringes and Mirikizumab Test Solution Formulation Using Investigational 1-Ml and 2-Ml Prefilled Syringes in Healthy Participants $20,794 1 payment
  9. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $16,920 4 payments
  10. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis $15,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record